All News
Vitamin D Headlines (5.9.2025)
Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow.com. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy.
Read Article
Osteoarthritis Risky Business (4.18.2025)
Dr. Jack Cush reviews the news and Journal reports from this week on RheumNow.com. Osteoarthritis patients have unique risks and synovial fluid WBC numbers can tell you when to worry about septic arthritis in gout and pseudogout patients.
Read Article
The Increasing Cost of First-Line Biologics for Plaque Psoriasis
A national commercial claims analysis of first-line use of biologics in biologic−naive plaque psoriasis patients found a near doubling of net treatment costs from 2007 to 2021 ($21 236 to $47 125).
Read Article
EMR Messaging Woes (4.11.2025)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com
Read Article
J&J announced results of Phase 3 ICONIC-TOTAL study of qd icotrokinra, an oral IL-23 receptor inhibitor, in 311 ps w/ difficult scalp and genital psoriasis (PSO) -success in 57%; skin clearance in 66% & genital psoriasis resp in 77% treated https://t.co/WftyEcDh8u https://t.co/Ydy37Eo0jX
Dr. John Cush RheumNow ( View Tweet)
Full read overview of Discoid Lupus. https://t.co/G6lXWTRSFn https://t.co/yjVsDg0D5d
Links:
Dr. John Cush RheumNow ( View Tweet)
TONIGHT! Tuesday Night Rheumatology: 🔓 Lupus Unlocked: Cutaneous SLE
Join us for a discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE.
Featuring:
Dr. Victoria P. Werth
Dr. Matilda Nicholas
Dr. Anthony Fernandez
Dr. Christopher https://t.co/l0QjM9obk2
Dr. John Cush RheumNow ( View Tweet)
Full read overview of Discoid Lupus. https://t.co/aXgveR2NwF https://t.co/9JK6CNqedO
Links:
Dr. John Cush RheumNow ( View Tweet)
Tuesday Night Rheumatology: 🔓 Lupus Unlocked: Cutaneous SLE
Join us for a discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE.
Featuring:
Dr. Victoria P. Werth
Dr. Matilda Nicholas
Dr. Anthony Fernandez
Dr. Christopher Richardson https://t.co/UNazbo9TuZ
Dr. John Cush RheumNow ( View Tweet)
Single-centre retrospective study, 27 children with refractory juvenile dermatomyositis (jDM) Rx with baricitinib (F/U of 25 mos)-- 77% (21/27) improved skin rashes (62% complete resolution) & Dz activity improved (6 vs 0.8, p<0.01) 70% (19/27) achieved inactive disease https://t.co/rRlhoY9O4q
Dr. John Cush RheumNow ( View Tweet)
Hyperpigmentation in SLE
Young complex SLE patient develops blue-grey/slate colored hyperpigmentation on her arms and legs - From?
Features Dr. Jack Cush
https://t.co/yoKU7rJp8y https://t.co/Kh0tZLJ8SX
Dr. John Cush RheumNow ( View Tweet)
Tuesday Night Rheumatology: 🔓 Lupus Unlocked: Cutaneous SLE
Join us for a discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE.
Featuring:
Dr. Victoria P. Werth
Dr. Matilda Nicholas
Dr. Anthony Fernandez
Dr. Christopher Richardson https://t.co/w7cYVNUI9t
Dr. John Cush RheumNow ( View Tweet)
An emulation trial shows that Humira biosimilars (Amjevita & Imraldi) were equivalent to Humira in psoriasis & achieving PASI <=2, both for new biologic starts and for biologic switchers. https://t.co/8lTGGs2rbP https://t.co/T6rTJ5ESj2
Dr. John Cush RheumNow ( View Tweet)
Bullhead Sign in #SAPHO Syndrome
▶️Synovitis,
▶️Acne
▶️Pustulosis
▶️Hyperostosis
▶️Osteitis
👉🏽https://t.co/ownI4Q543w
via @MayoProceedings https://t.co/FXlTtmsDDX
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
✅ Management of #REFRACTORY skin manifestations in patients with #LUPUS ➡️ my practical tips 💪 for #PANLAR2025 🇲🇽 https://t.co/KnJO0eXI4W
Laurent ARNAUD Lupusreference ( View Tweet)
JAMA Pt Education handout - Scleroderma https://t.co/UpK24WfyNF
Links:
Dr. John Cush RheumNow ( View Tweet)
JAMA Pt Education handout - Scleroderma https://t.co/UpK24WfyNF
Links:
Dr. John Cush RheumNow ( View Tweet)
Anti-muscarinic 3 Abs are assoc w/ severe GI Dz in systemic Sclerosis. 132 SSc pts (enrich for GI Sxs) - 39% had anti-M3R Abs; 25% high-titer M3R+. Hi titer M3R+ pts had more diffuse Dz (44% vs 23%), GI severity (91% vs 70%), RNPC3+ (18% vs 6%), U1RNP+(21 vs 2%) https://t.co/j8ZWFY4fgx
Dr. John Cush RheumNow ( View Tweet)
Sjogrens is a hot area in drug development: “Sjogren’s Syndrome Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs, including:
nipocalimab
VAY736 (ianalumab)
HZN-1116
AMG 329
R-2487 https://t.co/sVbyPLi2Um https://t.co/IlvthM7qyG
Links:
Dr. John Cush RheumNow ( View Tweet)
Patient info on Sweets Syndrome: acute febrile neutrophilic dermatosis
https://t.co/0q93q2NVc9 https://t.co/cE3LA8LaRQ
Links:
Dr. John Cush RheumNow ( View Tweet)
